Clinical trials: Clear Cell Renal Cancer
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Pediatric Solid Tumor, Germ Cell Tumor
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT03618381
- Testing
- second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Seattle Children's Hospital
Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally Advanced
- Trial name
- CANIQOL (NCT07028125)
- Testing
- cabozantinib and nivolumab
- Where
- 19 sites in France
- Volunteers
- 83 people
- Sponsor
- Centre Francois Baclesse
Kidney Cancer
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900536
- Testing
- mutation analysis, polymorphism analysis, protein expression analysis
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
SLM + Axitinib for Clear Cell RCC
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it…
- Trial name
- NCT02535533
- Testing
- Selenomethionine (SLM), Axitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mohammed Milhem
Kidney Cancer
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
RATIONALE: Tretinoin may help cells that are involved in the body's immune response to work better. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells.
- Trial name
- NCT00100906
- Testing
- IL-2, ATRA
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
This randomized pilot early phase I trial studies the side effects and how well nivolumab alone works compared to nivolumab with bevacizumab or ipilimumab before surgery in treating patients with kidney cancer, also referred to…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02210117
- Testing
- Bevacizumab, Biopsy, Ipilimumab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- SURTIME (NCT01099423)
- Testing
- timing of surgery, gene expression analysis, biologic sample preservation procedure
- Where
- 29 sites in Belgium, Canada and 3 more
- Volunteers
- 99 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
This phase I trial is studying the side effects and best way to give sunitinib malate in treating patients with unresectable or metastatic kidney cancer or other advanced solid tumors.
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer
- Trial name
- NCT00499135
- Testing
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer
Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow.
- Trial name
- NCT02885649
- Testing
- Enzalutamide, Laboratory Biomarker Analysis, Nephrectomy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rutgers, The State University of New Jersey
Renal Cell Carcinoma, Clear Cell
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W)…
- Trial name
- NCT06708949
- Testing
- Drugs Nivolumab, Ipilimumab, BMS-986213 (Relatlimab-Nivolumab FDC)
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer, Melanoma (Skin)
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276835
- Testing
- High-dose interleukin-2, genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
ccRCC
Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study
This retrospective study included 704 patients with ccRCC who underwent radical or partial nephrectomy. Patients were stratified into the LIPI good group and the intermediate/poor (int./poor) group based on dNLR (≥ 3) and LDH (≥…
- Trial name
- NCT06775574
- Where
- China
- Volunteers
- 704 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
- Trial name
- NCT06245915
- Testing
- AB-2100
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Arsenal Biosciences, Inc.
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic).
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03284385
- Testing
- Adavosertib
- Where
- 29 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT07768306
- Testing
- 68Ga-NYM096 injection
- Volunteers
- 20 people
- Sponsor
- Norroy Bioscience Co., LTD
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread…
- Conditions
- Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
- Trial name
- NCT07227415
- Testing
- PF-08634404, Ipilimumab, Axitinib
- Where
- 183 sites in United States, Australia and 4 more
- Volunteers
- 224 people
- Sponsor
- Pfizer